JAK Inhibitor News and Research

RSS
Yale researchers use arthritis medication to treat patient with disfiguring sarcoidosis

Yale researchers use arthritis medication to treat patient with disfiguring sarcoidosis

Study adds more evidence to underlying autoimmune mechanisms in type 1 diabetes

Study adds more evidence to underlying autoimmune mechanisms in type 1 diabetes

New treatment option could provide effective therapy for patients with dermatologic conditions

New treatment option could provide effective therapy for patients with dermatologic conditions

JAK inhibitors show promise in restoring hair growth in patients with alopecia areata

JAK inhibitors show promise in restoring hair growth in patients with alopecia areata

JAK inhibitors may be first effective treatment for people with alopecia areata

JAK inhibitors may be first effective treatment for people with alopecia areata

Research finding opens door to new treatment options for inflammatory rheumatism

Research finding opens door to new treatment options for inflammatory rheumatism

Targeted therapy for triple-negative breast cancer may prove beneficial

Targeted therapy for triple-negative breast cancer may prove beneficial

Researchers discover methods for reducing age-related stem cell dysfunction, metabolic disease in aged mice

Researchers discover methods for reducing age-related stem cell dysfunction, metabolic disease in aged mice

Imetelstat drug shows promise in treating patients with myelofibrosis

Imetelstat drug shows promise in treating patients with myelofibrosis

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

FDA extends action date for Pfizer’s tofacitinib NDA review

FDA extends action date for Pfizer’s tofacitinib NDA review

Tofacitinib efficacy suggested for rheumatoid arthritis

Tofacitinib efficacy suggested for rheumatoid arthritis

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma